By Fineline Cube 
China-based Sinocelltech Group Ltd (SHA: 688520) announced that it has received another indication approval from the National Medical Products Administration (NMPA) for its finotonlimab. The approval allows the use of the programmed-death 1 (PD-1) monoclonal antibody (mAb) in combination with Anbeizhu, Sinocelltech’s biosimilar version of Roche’s Avastin (bevacizumab), for the treatment of unresectable or metastatic hepatocellular carcinoma in patients who have not previously received systemic therapy.
Drug Profile
Finotonlimab first obtained NMPA approval last month for the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck when combined with platinum. Anbeizhu, on its part, was approved in China in June 2023 for the treatment of metastatic colorectal cancer, advanced, metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, hepatocellular carcinoma, epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, and cervical cancer.-Fineline Info & Tech